Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | FDPS | P14324 | 5/20 | 0.46 |
| ▸ | PGK1 | P00558 | 6/20 | 0.42 |
| ▸ | PGK2 | P07205 | 6/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533205 | 0.82 | FDPS (0.53) | FDPSBTN3A1PDE3ACYP2C9CYP2C19 | |
| SCHEMBL5897912 | 0.80 | PTPN1 (0.39) | PTPN1FDPSPGK1PGK2MEN1 | |
| SCHEMBL4725467 | 0.80 | FDPS (0.51) | FDPSBTN3A1PDE3ACYP2C9CYP2C19 | |
| SCHEMBL8146948 | 0.80 | PTPN1 (0.50) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL3075659 | 0.78 | PTPN1 (0.52) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL8353857 | 0.78 | PTPN1 (0.52) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL8149759 | 0.76 | PTPN1 (0.46) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL28669906 | 0.75 | PTPN1 (0.48) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL9244523 | 0.74 | PTPN1 (0.48) | PTPN1FDPSPGK1PGK2PTPN5 | |
| SCHEMBL9222814 | 0.74 | FDPS (0.50) | FDPSPGK1PGK2BTN3A1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005533-B2 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 (FR) | 2006-02-28 | — | — | US | disclosed |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 | 2004-12-30 | — | — | US | disclosed |
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS, 13 (FR) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | PTPN1 1016/4885FDPS 36/4885PGK1 86/4885 |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | PTPN1 1016/4885FDPS 36/4885PGK1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.